BC
MYGN icon

Broadfin Capital’s Myriad Genetics MYGN Stock Holding History

Broadfin Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-123,785
Closed -$3.44M – 48
2019
Q2 		$3.44M Sell
123,785
-116,215
-48% -$3.28M 0.75% 33
2019
Q1 		$7.97M Buy
+240,000
New +$7.31M 1.65% 26

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadfin Capital's MYGN Position: Q3 2019 in Review

Broadfin Capital sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 123,785 shares — an estimated $3.44M sold.

Broadfin Capital first reported a position in MYGN in Q1 2019 and held it in 2 quarters. The position peaked at $7.97M in Q1 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Broadfin Capital reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Broadfin Capital sold 123,785 Myriad Genetics shares in Q3 2019, an estimated $3.44M.
  • Broadfin Capital first reported a position in Myriad Genetics in Q1 2019 and held it in 2 quarters.
  • Broadfin Capital's Myriad Genetics position peaked at $7.97M in Q1 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.